REDWOOD CITY, Calif., Nov. 28 /PRNewswire-FirstCall/ -- Genomic Health, Inc. today announced that the company has signed a national contract with Aetna for Oncotype DX, the company’s test service that quantifies the likelihood of breast cancer recurrence and predicts the likelihood of chemotherapy benefit for a large portion of early-stage breast cancer patients. Aetna is one of the nation’s largest health benefits companies, with more than 15 million medical members. With the signing of the agreement with Aetna, the company has established health plan contracts for Oncotype DX covering an estimated 80 million lives.
This new agreement establishes payment rates across all of Aetna’s plans for members with early-stage breast cancer. Aetna began coverage for the test upon release of its Clinical Policy Bulletin (CPB) on August 25, 2006. The policy (CPB #0352) is available on Aetna’s web site at http://www.aetna.com/cpb/data/CPBA0352.html .
About Genomic Health
Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test service, Oncotype DX(TM), which has been shown to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit in early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit www.genomichealth.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including the estimated lives covered. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risk and uncertainties include the risks set forth in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2006, which is on file with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.
Genomic Health, Inc.
CONTACT: Brad Cole of Genomic Health, Inc., +1-650-569-2281, orinvestors@genomichealth.com; or media, Emily Faucette of WeissCommPartners, +1-415-946-1066, or media@genomichealth.com, for Genomic Health,Inc.
Web site: http://www.genomichealth.com//
